Targeting hypoxia in prostate cancer cells to increase treatment efficacy

Heather Nesbitt, niall byrne, Jenny Worthington, Stephanie McKeown, Declan McKenna

Research output: Contribution to journalArticle

Abstract

Androgen deprivation therapy e.g. bicalutamide (BCA) is widely used to treat advanced prostate cancer; however, within 1.5-3 years most tumours have progressed to androgen independence (Abate-Shen C; Genes Dev 14, 2410-2434; 2000). Previously we showed that daily BCA causes an initial profound hypoxia (
LanguageEnglish
Pages209-210
JournalUlster Medical Journal
Volume84
Issue number3
Publication statusPublished - Oct 2015

Fingerprint

Androgens
Prostatic Neoplasms
Temefos
Genes
Neoplasms
bicalutamide
Hypoxia
Therapeutics

Keywords

  • hypoxia
  • uHAP
  • OCT1002
  • bicalutamide
  • prostate cancer

Cite this

Nesbitt, Heather ; byrne, niall ; Worthington, Jenny ; McKeown, Stephanie ; McKenna, Declan. / Targeting hypoxia in prostate cancer cells to increase treatment efficacy. In: Ulster Medical Journal. 2015 ; Vol. 84, No. 3. pp. 209-210.
@article{e759c8a8ea72438d9a293179573de572,
title = "Targeting hypoxia in prostate cancer cells to increase treatment efficacy",
abstract = "Androgen deprivation therapy e.g. bicalutamide (BCA) is widely used to treat advanced prostate cancer; however, within 1.5-3 years most tumours have progressed to androgen independence (Abate-Shen C; Genes Dev 14, 2410-2434; 2000). Previously we showed that daily BCA causes an initial profound hypoxia (",
keywords = "hypoxia, uHAP, OCT1002, bicalutamide, prostate cancer",
author = "Heather Nesbitt and niall byrne and Jenny Worthington and Stephanie McKeown and Declan McKenna",
year = "2015",
month = "10",
language = "English",
volume = "84",
pages = "209--210",
journal = "Ulster Medical Journal, The",
issn = "0041-6193",
number = "3",

}

Nesbitt, H, byrne, N, Worthington, J, McKeown, S & McKenna, D 2015, 'Targeting hypoxia in prostate cancer cells to increase treatment efficacy', Ulster Medical Journal, vol. 84, no. 3, pp. 209-210.

Targeting hypoxia in prostate cancer cells to increase treatment efficacy. / Nesbitt, Heather; byrne, niall; Worthington, Jenny; McKeown, Stephanie; McKenna, Declan.

In: Ulster Medical Journal, Vol. 84, No. 3, 10.2015, p. 209-210.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeting hypoxia in prostate cancer cells to increase treatment efficacy

AU - Nesbitt, Heather

AU - byrne, niall

AU - Worthington, Jenny

AU - McKeown, Stephanie

AU - McKenna, Declan

PY - 2015/10

Y1 - 2015/10

N2 - Androgen deprivation therapy e.g. bicalutamide (BCA) is widely used to treat advanced prostate cancer; however, within 1.5-3 years most tumours have progressed to androgen independence (Abate-Shen C; Genes Dev 14, 2410-2434; 2000). Previously we showed that daily BCA causes an initial profound hypoxia (

AB - Androgen deprivation therapy e.g. bicalutamide (BCA) is widely used to treat advanced prostate cancer; however, within 1.5-3 years most tumours have progressed to androgen independence (Abate-Shen C; Genes Dev 14, 2410-2434; 2000). Previously we showed that daily BCA causes an initial profound hypoxia (

KW - hypoxia

KW - uHAP

KW - OCT1002

KW - bicalutamide

KW - prostate cancer

M3 - Article

VL - 84

SP - 209

EP - 210

JO - Ulster Medical Journal, The

T2 - Ulster Medical Journal, The

JF - Ulster Medical Journal, The

SN - 0041-6193

IS - 3

ER -